
We're building silicon-to-cell integration that collapses traditional discovery timelines
FAZENA leverages quantum chemistry and AI to design next-generation therapeutics through the first end-to-end in silico-to-cell platform. We transform computational predictions into experimentally validated therapeutic candidates. While our full pipeline is under construction, we're already accelerating pharma R&D through specialized services and our AI-powered SaaS platform.
We are actively advancing three strategic initiatives: developing novel therapeutics for neurodegenerative diseases, cancer, and diabetes; building integrated in silico and in vivo platforms to power our unified drug discovery pipeline; and partnering with pharmaceutical companies on targeted research projects.
An innovative approach in the design of the ABCA7 modulator was the use of modern tools that utilize transformers and deep neural networks to obtain the structures of mutant forms of this transporter protein. We achieved high-quality structures, which allowed us to further use this for molecular docking and dynamics, calculating binding and dissociation constants. At this stage, we are optimizing leads and expanding our understanding of what other genetic features and relationships between mutations of this protein and drug development may exist. We have now begun work on publishing a series of articles in scientific journals. Our work was highly praised at the Neuro Impact Challenge, where we took first place.

Obtaining the spatial structure of non-coding RNAs and finding therapeutic small molecules for this target. Modelling in intracellular conditions, molecular dynamics, refinement of the lead molecule using QM/MM methods, calculation of free binding energy and other parameters. The platform is not limited by target length.


Creation of rigid, structurally defined macrocycles with optimized binding, stability, and permeability through the use of a library of rationally selected non-canonical amino acids.
Design based on both structure-dependent and sequence-oriented approaches
Development of molecular glues that promote target degradation or enhanced interaction with PPI partners
Application to highly complex undruggable targets
Unique technical solutions for tissue-selective peptides
Comprehensive toolkit for computational drug design and biomolecular engineering.
Virtual screening of small molecules against your target (protein, RNA, DNA).
Research into the molecular mechanism of action of your small molecule.
Repurposing of known active pharmaceutical ingredients
Docking and molecular dynamics of the target-ligand complex (which may be protein-protein, protein-nucleic acid, or protein-peptide interactions).
Design of replacement therapy proteins, redesign of proteins with a known active site.
Design gRNAs for your target, structural binding verification.
Meet the minds reshaping drug discovery — specialists in bioinformatics, biochemistry, biotechnology, and synthetic biology working together to bring novel therapeutics from concept to reality.
Explore our most recent research papers, articles, and insights on the future of AI-driven drug discovery.



Join forces with FAZENA to accelerate drug discovery. Whether you're a research institution, pharmaceutical company, or biotech venture, let's collaborate to transform computational predictions into validated therapeutics.
Start a Conversation